Inpharma

Sublingual misoprostol compared with vaginal misoprostol for medical abortion
pp. 1-1(1)

Cold remedies and crystal meth: the debate over ephedrine
pp. 2-2(1)

Public & private health systems: on the same (balance) sheet?
pp. 3-3(1)

Stockpiling of candidate vaccine best bet for future flu pandemic
pp. 3-3(1)

UK NICE has recommended the use of varenicline as a treatment option for adults with a desire to quit smoking.
pp. 3-3(1)

UK NICE has recommended a scheme which would make bortezomib more accessible to UK NHS patients with multiple myeloma
pp. 3-3(1)

Unconditional statin treatment dominant for diabetics
pp. 4-4(1)

Tacrolimus tops steroids for atopic dermatitis
pp. 4-4(1)

Paclitaxel poliglumex produces cost savings in NSCLC
pp. 4-4(1)

News from ATC
pp. 5-5(1)

Which treatment option best value in paediatric empyema?
pp. 5-5(1)

Atypical antipsychotics elevate costs in schizophrenia
pp. 5-5(1)

R&D news from ASCO
pp. 6-6(1)

EVT 201, a partial positive allosteric modulator of the GABAA receptor complex, shows promise in patients with insomnia
pp. 6-6(1)

An intranasal formulation of ketorolac [ROX 888] provides effective pain relief after surgery
pp. 6-6(1)

Mymetics Corporation's HIV vaccine has demonstrated the first-ever stimulation of neutralising IgA antibodies in nonhuman primates
pp. 6-6(1)

CDB-4124 reduces both the duration and intensity of pain associated with endometriosis
pp. 6-6(1)

Sorafenib looking SHARP in advanced HCC
pp. 7-8(2)

Encouraging results with enclomifene in hypogonadism
pp. 8-8(1)

Dimebolin is beneficial in Alzheimer's disease
pp. 8-8(1)

Eltrombopag is an effective therapy for patients with chronic idiopathic thrombocytopenic purpura
pp. 8-8(1)

News from AHS
pp. 9-9(1)

Omega-3 fatty acid supplementation may be an effective adjuvant therapy for patients with inflammatory joint pain
pp. 9-9(1)

The addition of tocilizumab [Actemra] to a disease-modifying antirheumatic drug (DMARD) regimen improves rheumatoid arthritis
pp. 9-9(1)

FP 0011, a glutamate release inhibitor, improves Parkinsonian symptoms
pp. 9-9(1)

KB 2115, a first-in-class liver-selective thyroid hormone receptor agonist, shows promise in the treatment of lipid metabolism disorders
pp. 9-9(1)

Sinapultide SELECTed for gold STAR in preventing RDS
pp. 10-10(1)

Imidapril as effective as candesartan cilexetil for hypertension
pp. 10-10(1)

Rituximab plus chemotherapy is superior to chemotherapy alone in patients with indolent or mantle cell lymphoma
pp. 10-10(1)

The addition of lactoferrin and probiotics to standard triple therapy may be beneficial in patients with Helicobacter pylori infections
pp. 10-10(1)

Ziprasidone has similar effects on schizophrenic patients in a naturalistic setting as in more restricted clinical trials
pp. 11-11(1)

Prolonged warfarin use reduces the incidence of prostate cancer for men aged ≥ 50 years
pp. 11-11(1)

Hydrochlorothiazide + amiloride for stable exertional angina
pp. 11-11(1)

Chromium/biotin beneficial in overweight patients with T2DM
pp. 11-11(1)

Tenofovir comparable to adefovir for chronic hep B
pp. 11-11(1)

Therapy news from the American Society of Clinical Oncology
pp. 12-13(2)

Low-dose botulinum toxin A is effective for pain relief in patients with piriformis syndrome
pp. 13-13(1)

A combination of cisplatin, etoposide and slow-release lanreotide is effective for the treatment of patients with metastatic endocrine tumours
pp. 13-13(1)

The number of pills a patient is prescribed appears to have no major effect on their daily adherence to medication
pp. 13-13(1)

Reduction of cancer risk with vitamin D3 brought to light
pp. 13-13(1)

Considerable reductions in US coronary deaths - why?
pp. 14-14(1)

Stepped buprenorphine strategy equals conventional methadone
pp. 14-14(1)

Pioglitazone enhances flutamide plus metformin therapy in women with hyperinsulinaemic hyperandrogenism
pp. 14-14(1)

Alcohol dulls the pain
pp. 14-14(1)

Cetuximab an EXTREMEly important addition in SCCHN
pp. 15-15(1)

Preoperative trastuzumab, docetaxel and carboplatin therapy is effective for HER2-positive breast cancer
pp. 16-16(1)

Adjuvant mitotane shows benefits in adrenocortical carcinoma
pp. 16-16(1)

Weekly cladribine treatment is comparable to daily treatment in active hairy cell leukaemia
pp. 16-16(1)

Peginterferon vs interferon for hep C: more effective but more risk
pp. 16-16(1)

Zoledronic acid is an effective preventative or treatment of bone loss in men with HIV infections receiving HAART
pp. 16-16(1)

Guanfacine XR excels in ADHD
pp. 17-18(2)

Aerosolised tobramycin effective in CF P. aeruginosa infection
pp. 19-19(1)

Low-dose S 1 plus irinotecan shows potential as a regimen with minimal toxicity in advanced colorectal cancer
pp. 19-19(1)

Oral budesonide is effective in patients with chronic pouchitis resistant to standard antibiotic treatment
pp. 19-19(1)

Adalimumab for psoriatic arthritis unresponsive to DMARDs
pp. 19-19(1)

Immunisations greatly decrease the risk of sudden infant death syndrome
pp. 20-20(1)

Coadministration of etoricoxib and warfarin is unlikely to result in clinically important interactions
pp. 20-20(1)

Prolonged topotecan therapy is beneficial in patients with recurrent ovarian cancer resistant to platinum-based chemotherapy
pp. 20-20(1)

Ketorolac is an effective prophylactic analgesic for patients undergoing retinal detachment surgery
pp. 20-20(1)

Sildenafil improves sperm motility but may have adverse effects on male fertility
pp. 20-20(1)

A histrelin subdermal implant is effective in children with central precocious puberty
pp. 20-20(1)

FDA halts canfosfamide trials
pp. 21-21(1)

Ranitidine elevates risk of neonatal late-onset sepsis
pp. 21-21(1)

Haloperidol as a first-line delirium treatment "will not contribute to the establishment of drug therapy for delirium based on risk-benefit assessment"
pp. 21-21(1)

Non-trial duloxetine poorly tolerated
pp. 21-21(1)

Statins "safe" in standard doses
pp. 22-22(1)

Product launches in Japan
pp. 22-22(1)

EU product approvals
pp. 22-22(1)

US product approvals
pp. 22-22(1)

Other US regulatory news
pp. 23-23(1)

Bristol-Myers Squibb has launched abatacept [Orencia] in the UK for moderate to severe rheumatoid arthritis
pp. 23-23(1)

Health Canada has expanded the indication for clopidogrel [Plavix; sanofi-aventis, Bristol-Myers Squibb] to include patients with all acute coronary syndromes
pp. 23-23(1)

Mallinckrodt Brand Pharmaceuticals' oxycodone/paracetamol [oxycodone/acetaminophen; Magnacet] has been launched in the US
pp. 23-23(1)